Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00059215
Status:
COMPLETED
Last Update Posted:
2010-05-25
First Post:
2003-04-21
Brief Title:
A Trial of CS-747 Prasugrel Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention PCI
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Double-Blind Randomized Multicenter Dose-Ranging Trial of CS-747 Compared With Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effects of a drug known as CS-747 also known as prasugrel on subjects having a procedure called a percutaneous coronary intervention also referred to as PCI in which a doctor will attempt to open a blocked vessel or vessels in the heart using a catheter a long thin tube that has a small balloon on the end In many cases patients who have this procedure receive a stent a small wire spring that helps keep the vessel open
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H7T-MC-TAAH | OTHER | Eli Lilly and Company | None |